N4-Benzoylcytosine CAS 26661-13-2 Purity ≥99.0% Sofosbuvir Intermediate Factory

Short Description:

Name: N4-Benzoylcytosine

CAS: 26661-13-2

Appearance: White or Off-White Powder

Purity: ≥99.0% (HPLC) 

Intermediate of Sofosbuvir (CAS: 1190307-88-0) in the treatment of Hepatitis C Virus (HCV)

High Quality, Commercial Production 

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Sofosbuvir Related Intermediates:

26661-13-2 - Chemical Properties:

Name N4-Benzoylcytosine
CAS Number 26661-13-2
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C11H9N3O2
Molecular Weight 215.21
Density 1.33±0.10 g/cm3
Melting Point >300℃(dec.) (lit.)
COA & MSDS Available
Origin Shanghai, China
Shelf Life  36 Months if Stored Properly
Brand Ruifu Chemical

26661-13-2 - Specifications:

Item Specifications
Appearance White or Off-White Powder
Identification HPLC
Purity / Analysis Method ≥99.0% (HPLC)
Moisture (K.F) ≤0.50%
Loss on Drying ≤0.50%
Residue on Ignition ≤0.50%
Cytosine ≤0.50%
Heavy Metals  ≤20ppm
Test Standard Enterprise Standard
Application  Intermediate of Sofosbuvir (CAS: 1190307-88-0)  

Package & Storage:

Package: Bottle, Aluminum foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture 

Advantages:

1

FAQ:

www.ruifuchem.com

26661-13-2 - Risk and Safety:

Hazard Symbols Xi - Irritant
Risk Codes R20/22 - Harmful by inhalation and if swallowed.
R36/37/38 - Irritating to eyes, respiratory system and skin.
Safety Description
S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
S36 - Wear suitable protective clothing.
WGK Germany 3
HS Code 2933599099

26661-13-2 - Application:

Sofosbuvir (CAS: 1190307-88-0) is a drug used for the treatment of hepatitis C. It is recommended to be used in combination with other drugs (such as velpatasvir) for the first-line treatment for HCV genotypes 1, 2, 3, 4, 5, and 6. It takes effect through acting as a nucleotide analog inhibitor, being capable of specially inhibiting the HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Oral sofosbuvir was generally well tolerated in patients with chronic hepatitis C. 

  • Write your message here and send it to us